Preprint: Allele-specific antisense strategy rescues retinal function across diverse RHO mutations in preclinical models
Researchers describe SNARE, an antisense oligonucleotide approach that selectively silences mutant rhodopsin transcripts regardless of the underlying pathogenic variant, using a common SNP as an allele discriminator.
A preprint posted to bioRxiv on 1 September 2026 presents SNARE (SNP-guided Silencing of Aberrant RHO Expression), an antisense oligonucleotide (ASO) strategy designed to treat autosomal dominant retinitis pigmentosa (adRP) caused by mutations in the RHO gene, which encodes rhodopsin.
Autosomal dominant retinitis pigmentosa linked to RHO is characterised by extensive allelic heterogeneity: hundreds of distinct pathogenic variants have been identified, which has historically made mutation-specific gene therapy approaches impractical to scale. SNARE addresses this by targeting a common, benign single-nucleotide polymorphism (SNP) — c.-26A/G — as an allelic discriminator, enabling selective suppression of the mutant RHO transcript irrespective of which downstream pathogenic variant is present.
In preclinical models, the authors report potent functional rescue and preservation of retinal architecture. The strategy is described as mutation-agnostic and allele-specific, meaning it does not require a patient-specific therapeutic to be developed for each of the many known RHO variants.
The work is of interest to researchers in inherited retinal disease, gene therapy, and RNA therapeutics, and to genetic counsellors and educators working with families affected by dominant retinal dystrophies. The preprint has not yet undergone peer review, and the approach remains at the preclinical stage.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Retinitis pigmentosa is a group of inherited conditions that cause the cells in the retina — the light-sensitive layer at the back of the eye — to break down over time, leading to progressive loss of vision. One common form is caused by faults (mutations) in a gene called RHO, which carries instructions for making a protein called rhodopsin.
Researchers have described a new laboratory approach called SNARE, designed to work across many different RHO faults at once, rather than needing a separate treatment for each one. It uses a type of molecule called an antisense oligonucleotide — a short piece of engineered genetic material — to selectively quieten the faulty copy of the RHO gene while leaving the working copy alone.
In laboratory models, the approach preserved retinal structure and function. This work is at an early, preclinical stage and has not yet been tested in people. It has also not yet been reviewed by independent scientific experts (it is a preprint).
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary sourcePreprint bioRxiv (Cold Spring Harbor Laboratory) · 2026-09-01A mutation-agnostic and allele-specific ASO strategy demonstrates potent functional rescue and retinal preservation in RHO-linked retinitis pigmentosa